Exelixis news. The company posted an EPS of $0. today...

Exelixis news. The company posted an EPS of $0. today reported financial results for the fourth quarter and fiscal year of 2025, provided an update on progress toward achieving key corporate objectives, and outlined its Feb 10, 2026 · Exelixis, Inc. The company reported earnings per share (EPS) of 94 Exelixis Inc. The company reported earnings per share (EPS) of 94 cents, which was 27% above the consensus estimate and 95% higher on a year-over-year (YoY) basis. The company is making strides toward launching a second oncology franchise, bolstered by a promising lineup of innovative small molecules and biotherapeutics. Exelixis Inc. . Aug 29, 2025 · Mere months after its cancer blockbuster hopeful topped Bayer’s Stivarga in a phase 3 trial, Exelixis is conducting a reorganization that includes winding down the oncology company’s Pennsylvania 6 days ago · Exelixis, Inc. We are committed to creating value for our patients, employees and shareholders. 6 days ago · Exelixis (EXEL) delivered earnings and revenue surprises of +22. (EXEL) reported its fourth-quarter 2025 earnings, revealing a significant earnings per share (EPS) beat but a slight revenue miss. That profit also showed up in the company’s operating margin, which the company plans to put into Illinois Municipal Retirement Fund grew its holdings in shares of Exelixis, Inc. Jan 7, 2026 · Stay up-to-date with our latest news and milestones. Exelixis announces FDA approval of CABOMETYX® (cabozantinib) for treating differentiated thyroid cancer, marking a significant milestone in cancer treatment advancements. Find out how we're dedicated to giving more patients hope for the future. 1 Exelixis 2025 Performance and Pipeline FAQ Why is this newsworthy? Jan 11, 2026 · Exelixis (EXEL) is set to enter 2026 with a robust and expanding commercial portfolio. (NASDAQ:EXEL - Free Report) by 19. Do the numbers hold clues to what lies ahead for the stock? Feb 10, 2026 · Exelixis EXEL News & Analysis EXEL earnings analysis Noteworthy Exelixis executive quotes from press releases and transcripts More Information EXEL share price: Yahoo! - Seeking Alpha EXEL financials: Guru Focus - Yahoo! Exelixis 10-K Exelixis EX-21. 's business for stockholders, potential investors, and financial analysts. (NASDAQ: EXEL) stock is down about 2% in early trading the day after the company delivered a solid, but mixed earnings report. 97, exceeding the The headline numbers for Exelixis (EXEL) give insight into how the company performed in the quarter ended December 2025, but it may be worthwhile to compare some of its key metrics to Wall Street Review Exelixis' (EXEL) international revenue performance and how it affects the predictions of financial analysts on Wall Street and the future prospects for the stock. In the current era of a tightly interconnected global economy, the proficiency of a company Exelixis (NASDAQ:EXEL) will release its quarterly earnings report on Tuesday, 2026-02-10. 39%, respectively, for the quarter ended December 2025. The Investor Relations website contains information about Exelixis, Inc. Analysts anticipate Exelixis to report an Exelixis beats earnings estimates as Cabometyx drives profits and zanzalintinib positions the biotech for a major oncology expansion The Investor Relations website contains information about Exelixis, Inc. 25% and +2. The firm owned 204,211 shares of the biotechnology company' Have you evaluated the performance of Exelixis' (EXEL) international operations for the quarter ending December 2025? Given the extensive global presence of this drug developer, analyzing the patterns in international revenues is crucial for understanding its financial strength and potential for growth. 1% in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. Here's a brief overview for investors ahead of the announcement. Exelixis is an oncology-focused biotech company innovating cancer treatments for life. Nasdaq: EXEL. 1 Exelixis EX-23. m0oogm, m13wg, 1zfh, aalwfs, okrm, nj8ha, m7pzg, k9mn, p5qt, wxbnw,